Company intelligence / Profile preview

American Gene Technologies

Rockville, Maryland, United States

Ownership: Private
Development stage: Other

Overview

AGT’s lead program AGT103-T completed a Phase Ia trial in HIV with no serious adverse events and evidence of engraftment and persistence of modified T cells. The company has launched Addimmune as a subsidiary to advance the HIV cure into Phase Ib trials. Other programs are at preclinical or early clinical stages.[6][8][10]

Therapeutic areas: OncologyMetabolic DisordersInfectious Diseases
Modalities: Autologous cell therapy (genetically modified T cells)Lentiviral vector-based gene therapy[1][7][9]
Industry: Biotech

Drug pipeline

2 assets

AGT103-T

1 more asset in the full pipeline.

Request access →

Partnerships

Collaborations with NIAID on peer-reviewed research articles [4], but no major pharma partnerships disclosed.

Beyond the preview

Go deeper on American Gene Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on American Gene Technologies.

Explore the full profile